Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Last updated: April 27, 2021
Sponsor: Hanan Jafar
Overall Status: Active - Recruiting

Phase

1

Condition

Osteoarthritis

Treatment

N/A

Clinical Study ID

NCT02963727
AlloKneeUJCTC
  • Ages 42-75
  • All Genders

Study Summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Severe KOA stage III or IV by Laurance & Kellgren staging as judged byPosterioranterior (PA) Xray of the knee joint.
  • Willing to participate by signing the informed consent

Exclusion

Exclusion Criteria:

  1. Sublaxation beyond 20 degrees of the bones of the knee joint
  2. Oral anticoagulants or heparin therapy
  3. Heart failure or arrhythmia
  4. Body Mass Index > 35
  5. Uncontrolled Diabetes Mellitus.
  6. Evidence of Infectious Diseases.
  7. Active infection
  8. Malignancy
  9. Pregnancy
  10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than
  12. Unreliable patients
  13. Non-resident in Jordan

Study Design

Total Participants: 10
Study Start date:
January 27, 2017
Estimated Completion Date:
December 31, 2021

Study Description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Connect with a study center

  • Cell Therapy Center

    Amman, 11942
    Jordan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.